AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) shares were up 1.2% during mid-day trading on Tuesday . The company traded as high as $2.06 and last traded at $2.00. Approximately 146,174 shares traded hands during trading, a decline of 95% from the average daily volume of 2,745,090 shares. The stock had previously closed at $2.02.

AEZS has been the subject of a number of recent analyst reports. Maxim Group set a $2.00 price target on AEterna Zentaris and gave the company a “buy” rating in a research note on Saturday, July 1st. HC Wainwright set a $3.00 price target on AEterna Zentaris and gave the company a “buy” rating in a research note on Wednesday, July 5th. Zacks Investment Research raised AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, ValuEngine raised AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $4.00.

The company’s 50 day moving average price is $1.93 and its 200 day moving average price is $1.91. The company’s market capitalization is $32.02 million.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.05). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.22 million. AEterna Zentaris had a negative return on equity of 514.64% and a negative net margin of 1,945.78%. The firm’s quarterly revenue was up 153.1% compared to the same quarter last year. Equities analysts predict that AEterna Zentaris Inc. will post ($1.02) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “AEterna Zentaris Inc. (AEZS) Trading Up -1.2%” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.